Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey. Professional guidelines say that when pulmonary ...
Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...
A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...
Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...
PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...
Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...
Piper Sandler adjusted its outlook on Keros Therapeutics (NASDAQ:KROS), significantly reducing the price target from $40.00 ...
The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...
2008;1(6):749-757. Current drugs available for the treatment of primary arterial hypertension (PAH) do not markedly improve survival and novel therapeutic strategies are required. Bone ...
A body weight-adjusted regimen of Uptravi dosing for children and adolescents with PAH was deemed appropriate, according to a ...
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback